Sema4D Knockout Attenuates Choroidal Neovascularization by Inhibiting M2 Macrophage Polarization Via Regulation of the RhoA/ROCK Pathway
Investigative Ophthalmology & Visual Science · 24.06.2024 · 65 (6) · 34
DOI: 10.1167/iovs.65.6.34 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, erschienen am 24.06.2024. Verfasst von Kaixuan Cui und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and …. Hauptthemen laut MEDLINE: Choroidal Neovascularization, Macrophages, rho-Associated Kinases, rhoA GTP-Binding Protein. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
The aim of this study was to elucidate the role of Sema4D in the pathogenesis of senescence-associated choroidal neovascularization (CNV) and to explore its underlying mechanisms.
Methods
In this study, we utilized a model of laser-induced CNV in both young (3 months old) and old (18 months old) mice, including those with or without Sema4D knockout. The expression and localization of Sema4D in CNV were assessed using PCR, Western blot, and immunostaining. Subsequently, the morphological and imaging examinations were used to evaluate the size of CNV and vascular leakage. Finally, the expression of M2 markers, senescence-related markers, and molecules involved in the RhoA/ROCK pathway was detected.
Results
We found that Sema4D was predominantly expressed in macrophages within CNV lesions, and both the mRNA and protein levels of Sema4D progressively increased following laser photocoagulation, a trend more pronounced in old mice. Moreover, Sema4D knockout markedly inhibited M2 polarization in senescent macrophages and reduced the size and leakage of CNV, particularly in aged mice. Mechanistically, aging was found to upregulate RhoA/ROCK signaling, and knockout of Sema4D effectively suppressed the activation of this pathway, with more significant effects observed in aged mice.
Conclusions
Our findings revealed that the deletion of Sema4D markedly inhibited M2 macrophage polarization through the suppression of the RhoA/ROCK pathway, ultimately leading to the attenuation of senescence-associated CNV. These data indicate that targeting Sema4D could offer a promising approach for gene editing therapy in patients with neovascular age-related macular degeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
- Yale College, Yale University, New Haven, Connecticut, United States.
Zitieren
APA
Cui, K., Tang, X., Yang, B., Fan, M., Hu, A., Wu, P., Yang, F., Lin, J., Kong, H., Lu, X., Yu, S., Xu, Y., & Liang, X. (2024). Sema4D Knockout Attenuates Choroidal Neovascularization by Inhibiting M2 Macrophage Polarization Via Regulation of the RhoA/ROCK Pathway. Investigative Ophthalmology & Visual Science, 65(6), 34. https://doi.org/10.1167/iovs.65.6.34
Vancouver
Cui K, Tang X, Yang B, Fan M, Hu A, Wu P, et al. Sema4D Knockout Attenuates Choroidal Neovascularization by Inhibiting M2 Macrophage Polarization Via Regulation of the RhoA/ROCK Pathway. Investigative Ophthalmology & Visual Science. 2024;65(6):34. doi:10.1167/iovs.65.6.34
BibTeX
@article{Cui2024,
author = {Cui, Kaixuan and Tang, Xiaoyu and Yang, Boyu and Fan, Matthew and Hu, Andina and Wu, Peiqi and Yang, Fengmei and Lin, Jicheng and Kong, Haolin and Lu, Xi and Yu, Shanshan and Xu, Yue and Liang, Xiaoling},
title = {Sema4D Knockout Attenuates Choroidal Neovascularization by Inhibiting M2 Macrophage Polarization Via Regulation of the RhoA/ROCK Pathway},
journal = {Investigative Ophthalmology & Visual Science},
year = {2024},
volume = {65},
number = {6},
pages = {34},
doi = {10.1167/iovs.65.6.34}
}
EUVIMED